| Target Price | ¥26,826.00 |
| Price | ¥19,555.00 |
| Potential |
37.18%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Ibiden 2027 .
The average Ibiden target price is ¥26,826.00.
This is
37.18%
register free of charge
¥31,500.00
61.08%
register free of charge
¥9,292.00
52.48%
register free of charge
|
|
| A rating was issued by 21 analysts: 18 Analysts recommend Ibiden to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ibiden stock has an average upside potential 2027 of
37.18%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 416.20 | 545.31 |
| 12.66% | 31.02% | |
| EBITDA Margin | 14.90% | 37.32% |
| 15.62% | 150.42% | |
| Net Margin | 15.31% | 14.72% |
| 67.80% | 3.84% |
19 Analysts have issued a sales forecast Ibiden 2027 . The average Ibiden sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Ibiden EBITDA forecast 2027. The average Ibiden EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Ibiden Analysts have issued a net profit forecast 2027. The average Ibiden net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 214.91 | 285.58 |
| 90.02% | 32.88% | |
| P/E | 68.48 | |
| EV/Sales | 9.22 |
19 Analysts have issued a Ibiden forecast for earnings per share. The average Ibiden EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


